Detailed Narrative
Pulsed Field Ablation (PFA) Leadership
Medtronic's Cardiac Ablation Solutions (CAS) business grew 22%, driven by its PFA portfolio, including Affera and PulseSelect platforms. Affera is highlighted as a "workhorse platform" with integrated high-density mapping and both PF and RF capabilities, increasing revenue per case. The company expects rapid growth to continue, with CAS projected to be a $1 billion business this fiscal year and line of sight to $2 billion. Supply chain improvements, particularly from the new Galway factory, are supporting this demand.
Renal Denervation (RDN) Market Opportunity
The company is poised to change the standard of care for uncontrolled hypertension with its Symplicity blood pressure procedure. A pivotal development occurred with CMS opening a national coverage analysis (NCA), expected to result in Medicare coverage within 8 months. This is anticipated to be an immediate and significant growth driver, addressing a massive unmet need in a patient population where current treatments are insufficient. International reimbursement efforts are ongoing, with China approval and France reimbursement established.
Robotics (Hugo) Progress and Milestones
Medtronic is making significant progress with its Hugo soft tissue robotic platform, with procedure volume more than doubling year-over-year in international markets. Key milestones include an upcoming FDA submission for urology indications by the end of next month, completion of enrollment in Hernia and benign GYN studies, and FDA approval to initiate a GYN oncology IDE study. Feature enhancements like ICG fluorescent imaging and LigaSure vessel sealing technology are also being integrated, positioning Hugo as a growth driver for the surgical business in FY26 and for Medtronic in the midterm.
Neuromodulation Innovation
The Neuromodulation segment grew 13%, driven by game-changing innovation in closed-loop sensing technology for both pain stimulation and brain modulation. The Inceptiv closed-loop spinal cord stimulator led to 17% U.S. growth in Pain Stim, while the Percept DBS systems, including the recently CE Mark cleared BrainSense Adaptive DBS for Parkinson's, drove 26% U.S. growth in Brain Modulation. These personalized, closed-loop systems are expected to drive continued above-market growth.
Diabetes Growth and Pipeline
The Diabetes business achieved its fifth consecutive quarter of double-digit growth (10%), primarily due to the market shift to AID systems and the strength of the MiniMed 780G system. High CGM attachment rates and strong consumables growth are noted. The Simplera Sync sensor, submitted for U.S. FDA approval, and integration with an Abbott-based sensor are expected to accelerate U.S. growth. The pipeline includes next-gen pumps, patch pumps, smart pens, algorithms, and expanded labeling for 780G for Type 2 diabetes, with an FDA filing expected in H1 CY25.
U.S. Surgical Distributor Dynamics
U.S. Surgical performance was impacted by a temporary change in distributor buying patterns, reducing growth by approximately 200 basis points in Q3. This involved two large distributors reducing inventory levels to meet their own goals. Management expects this issue to resolve as distributors reach target inventory levels by Q1 FY26, emphasizing that end-customer purchases remain stable and no market share loss has occurred. The business is performing well outside the U.S., with mid-single-digit growth globally and high single-digit growth in emerging markets.
Cardiovascular Portfolio Strength
The overall Cardiovascular portfolio grew mid-single digits, with strong performances in Cardiac Pacing Therapies (9% growth, 10 consecutive quarters of upper single-digit growth driven by Micra and conduction system pacing) and Structural Heart (high single-digit growth excluding congenital, with good adoption of Evolut FX+ TAVR system). Upcoming data catalysts for Evolut (5-year low-risk data at ACC, 2-year SMART trial data) are expected to further solidify this business.